Descoberta de medicamentos: visão geral

Drug discovery involves four key stages: target identification, hits identification, lead generation and optimization, and drug candidate identification. First, molecular targets like receptors and enzymes are identified using biochemical assays and computational methods. Next, high-throughput screening identifies hit molecules that bind to the target. Leads are then generated and optimized for potency, selectivity, and reduced adverse effects before final drug candidates are selected.

Molecular targets such as receptors, enzymes, and functional proteins are identified using biochemical assays, genetic interactions, and computational methods. These targets are the specific biological molecules that drugs will interact with to produce therapeutic effects. Identifying the correct target is the critical first step in drug discovery, as it guides all subsequent screening and optimization efforts.

High-throughput screening evaluates thousands of chemically synthesized compounds or natural products to identify hits—molecules that bind to the selected biological target. This rapid screening process narrows down vast compound libraries to a manageable number of promising candidates. Hits that pass primary screening are then modified to generate leads showing pharmacological activity against the chosen target.

Lead compounds are optimized through combinatorial chemistry to improve potency, target selectivity, and reduce adverse effects. Leads undergo testing for pharmacokinetics and bioavailability to ensure they work effectively in the body. Animal studies assess the compound's activity in vivo, potential adverse effects, and oral availability. Only compounds meeting these criteria advance to preclinical development.

Drug candidates are tested at multiple levels: molecular assays like receptor binding assays evaluate target interaction; cell function studies determine whether the drug acts as an agonist, antagonist, or inverse agonist; and whole animal studies assess effects on organ systems and disease models. These comprehensive tests identify lead compounds with desired pharmacological activity and selectivity for further development.

Many factors hinder progress in drug discovery, including the inability to optimize lead compounds or failure to produce desired effects in animal models. Lead optimization is time-consuming and challenging, with only a small percentage of projects succeeding. Compounds must demonstrate efficacy, safety, and appropriate pharmacokinetic properties across multiple testing phases before advancing to clinical trials.

Hits are initial molecules identified through high-throughput screening that bind to the biological target. Leads are hits that have been chemically modified to show pharmacological activity against the target. Leads represent a more advanced stage, having demonstrated functional effects beyond simple binding, and serve as the basis for further chemical modification and optimization.